Axial3D uses advanced artificial intelligence (AI) technologies to automatically create 3D reconstructions of individual organs or pathologies. These images will be available to view in the Bleepa platform and can subsequently be turned into 3D printed models in a variety of materials.
As a result of Axial3D's AI imaging technology being integrated with Bleepa, front-line clinicians will be able to request Axial3D image renderings from within Bleepa, clicking through to Axial3D's system while the supporting DICOM (the standard format for medical images) study will be automatically pushed by Bleepa to Axial3D.
Feedback said Axial3D will enter into its own commercial relationship with customers, but Bleepa will act as the user access point and will facilitate the data transfer on its behalf, with the customer's permission and following the agreed data processing arrangements between the customer and Axial3D.
The commercial agreement will enable joint- and cross-selling of both products through each company's distribution channels to new and existing customers, enabling both organisations to grow collaboratively.
Under the agreement, Feedback will receive a commission for each user-generated image request from Axial3D. This is the first example of Feedback's strategy to leverage its growing user base to generate supplementary revenue, over and above the main user licence fee.
"The addition of 3D imaging and printing enhances our value proposition to Bleepa users and re-enforces our vision to bring clinicians together, armed with the tools and information they need to make better-informed decisions faster,” said Tom Oakley, the chief executive officer of Feedback in a statement.
“We hope that Bleepa will make Axial's technology even more accessible to a wider clinical user base and that our partnership will help to drive the adoption of this key technology into the mainstream of front-line care. This important milestone confirms our strategy of becoming a gatekeeper platform for third-party technologies in order to generate additional revenues beyond the Bleepa user licence,” he added.
Roger Johnston, Oakley’s counterpart at Axial3D, said integrating with Bleepa would mean 3D imaging would become available as standard for clinical teams that are planning for surgical operations.
“We believe that Bleepa will transform surgical team collaboration across the NHS and beyond and Axial3D is delighted to be going on that journey with such a game-changing partner,” Johnston said.